STOCK TITAN

Mersana Therapeutics Inc - MRSN STOCK NEWS

Welcome to our dedicated news page for Mersana Therapeutics (Ticker: MRSN), a resource for investors and traders seeking the latest updates and insights on Mersana Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mersana Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mersana Therapeutics's position in the market.

Rhea-AI Summary
Mersana Therapeutics, Inc. (MRSN) provided a business update, reporting financial results for Q4 and full year 2023. The company is advancing Phase 1 clinical trials of XMT-1660 and XMT-2056, with plans to disclose initial clinical data in mid-2024. Collaboration with Johnson & Johnson and Merck KGaA continues. Cash, cash equivalents, and marketable securities as of December 31, 2023, were $209.1 million, supporting operations into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.58%
Tags
earnings
-
Rhea-AI Summary
Mersana Therapeutics, Inc. (MRSN) will be presenting at upcoming investor conferences to discuss their pipeline of antibody-drug conjugates targeting cancers. Live webcasts and archived replays will be available on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.17%
Tags
conferences
-
Rhea-AI Summary
Mersana Therapeutics, a clinical-stage biopharmaceutical company, will report its Q4 and full-year financial results on February 28, 2024. The company focuses on developing antibody-drug conjugates for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
conferences
Rhea-AI Summary
Mersana Therapeutics, Inc. will participate in a fireside chat at Guggenheim’s 6th Annual Biotechnology Conference on February 8, 2024. The company is a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.96%
Tags
conferences
-
Rhea-AI Summary
Mersana Therapeutics, Inc. (NASDAQ: MRSN) announced business updates, expected 2024 milestones, and an upcoming presentation at the 42nd Annual J.P. Morgan Healthcare Conference. The company continues to advance its Phase 1 clinical trials of XMT-1660 and XMT-2056, with plans to initiate expansion and advance dose escalation in 2024. Mersana also expects that its available funds will support its current operating plan commitments into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
conferences
-
Rhea-AI Summary
Mersana Therapeutics, Inc. (NASDAQ:MRSN) granted an inducement award of 12,205 shares of its common stock to a new employee. The award was granted in accordance with Nasdaq Listing Rule 5635(c)(4) and will vest in equal annual installments over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Mersana Therapeutics, Inc. provided a business update and reported financial results for the third quarter ended September 30, 2023. The company is advancing dose escalation of XMT-1660 and preparing to resume enrollment for XMT-2056 in Phase 1 clinical trials. Capital resources are expected to support operating plan commitments into 2026. The company also reported net cash used in operating activities, and collaboration revenue for the quarter. Mersana will host a conference call today at 8:00 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
earnings
-
Rhea-AI Summary
Mersana Therapeutics, Inc. will provide business updates and report its financial results for Q3 2023 on November 7, 2023. The company will host a conference call and webcast at 8:00 a.m. Eastern Time. A live webcast will be available on the Mersana website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
conferences earnings
-
Rhea-AI Summary
Mersana Therapeutics announces that the FDA has lifted the clinical hold on the Phase 1 clinical trial of XMT-2056, a systemically administered Immunosynthen STING-agonist ADC targeting HER2. The starting dose has been lowered based on clinical data, and the trial will evaluate safety, tolerability, exposure, and anti-tumor activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.21%
Tags
clinical trial
Rhea-AI Summary
Mersana Therapeutics announces retirement of Anna Protopapas as President and CEO, with Martin Huber named as her successor. Brian DeSchuytner appointed as Chief Operating Officer and Mohan Bala as Chief Development Officer. Additional changes to the executive team also announced.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.89%
Tags
none
Mersana Therapeutics Inc

Nasdaq:MRSN

MRSN Rankings

MRSN Stock Data

544.65M
64.31M
1.33%
95.9%
5.89%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About MRSN

mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.